when opk TEMPORARILY dropped a paltry thirty cents, Wait UNTIL MONDAY, this is an omen. Fact is those FOOLS that sold AH, are out MONEY, those that listened to the MESIAHMORON, are also out if they sold the open, PATHETIC.
Frosts NEXT two out license deals, in the works. With that much cash maybe 1.5B FROST will be lethal.
Birdie Birdie in the sky, why you do that in the short guy's eye. WE Know he can't see, but to do that birdie, well, good job birdie, good job birdie.
Birdie though your aim was true, it truly was a wasted poo. Hitting the EYE of one who can not see, birdie birdie shame on you, that was a wasted poo. Still, good job birdie.
My Fri. having fun post.
Long, Miami fan.
Thank you Drangles, I do believe the next two partnerships Frost Alluded to combined will garner near 800m-1B, 1B plus 400m in buying power Frost will be lethal. Shorts will CRAWL away bleeding impaled by FROSTICICLES, or is that icicles?
LONG, A Miami fan.
I stated earlier in a post with far less detail that today's move was bullish. So I agree with your sentiment. Last earnings call Frost ALLUDED to the potential for a partnership deal. His Exact WORDS are " Out licensing, yes. I would just say this that we received expressions of interest frequently from companies that are interested in our products for distribution and they come from American companies, and very often companies outside of the United States. And we consider them all. And at the moment we haven't signed any agreements of this sort, but we'll be sure to let you know as soon as we do, if we do." The Pfe deal was announced shortly thereafter.
He made a very similar statement today, Saying to me, stay tuned, hemophilia is on the block. He also said Partnerships FOR RAYALDEE in Asia and Europe if you read between the very clear lines.
Good morning. I’d like to give you a little perspective of what’s going on at OPKO. We’ve talked a bit about the licensing partnership deal with Pfizer on the one product, the human growth hormone. We consider this to be an exceptionally good deal. What’s a good deal?
A good deal is one which is successful for both sides, which is meaningful for both sides. From OPKO’s point of view the deal was exceptionally good in that we were able to recover or will have recovered almost the entire price we paid for the acquisition of PROLOR and then go onto enjoy the benefits of royalties and profit sharing once the product of human growth hormone is on the market.
From Pfizer’s point of view, it’s a very good deal we believe, in that as a leader in the marketing of human growth hormone and they have approximately $700 million to $750 million in worldwide sales and with the roaming [ph] of more than once a week injectable form of the drug presently the drug has to be given daily, they need it to protect their market.
Now with the tremendous muscle of Pfizer’s marketing and sales group internationally we all feel that they will be able to capture a significant part of the market for the daily product and so they will be competing with an advanced products against fewer products than they are competing against now so it’s entirely possible that their overall sales could exceed even and profits also with sharing in those profits with OPKO. So, it’s a good deal from their side, it’s a very good deal from our side.
And by the way, the arrangement is that we will share in the profits eventually not only of the once weekly, but in their daily product as they continue to go on.
The average down day 6 prior earnings .12, today .13. Bullish recovery.
You are RIGHT on with that assessment Dr.
Would be funny if it closed green though.
I am betting on 14.46-14.48 close, But I like your Boss'? number better.
would surprise me.
4.71 billion. Once again I did not make the list, GO FIGURE.
Miami, you trying to make me blush, lol. My opinion on opko has no impact on opk's price per share, none, zilch, just like this board. This board could vanish tomorrow, and Opko will trade up and down without it. The pipeline will advance or fail, opko will create partnerships, sell it's drugs in Asia and Europe, and nothing said here by ANY of us will impact these events. That I am oracling on, and it is the only thing I am 100% sure of.
But thanks for the complement, wink.
Look at the earnings estimates for the last 4 and next Q, all losses, 10, 9, 7, 6, 5. So they keep lowering them, but fact losses have been 11, .06, .11, .12. Three misses 1 beat. Revenue growth is not keeping pace with these overly optimistic analysts even though revenue is growing. Think they are picking these estimates out of think air, we lose .12, so they go from .06 to .05 ???? Yet we are starting 2 new phase studies, they should be expecting .14 loss.
My opinion which means little, lol. The earnings were about as expected. The analysts keep hanging at about .05-.06 loss, as Opko has doubled R&D spend. Three of last 4 earnings loss right at .11-.12, yet note they lowered next Q loss once again in the past 90 days. Good excuse for profit taking by some after this run up, or for shorts to cover. They beat on revenue, had fairly large paper losses, cash burn only 22m, so I thought earnings were all one could expect. The disconnect with these analysts is they miss on two fronts, increased R&D, and 4k sales. 4k sales are not going to do ANYTHING until after inclusion in the NCCN guidelines, and insurance kicks in.
This is a prebiopsy test, not a psa test, with about 1m biopsies a year that is the potential market. With the number of Drs. using the test currently, if 1/2 their patients opt to use the test, in a year that would only be about 1- 2% penetration. This is going to take time, as stated, needs NCCN, and insurance, it does NEED BOTH.
Now if you were asking about the price action, last Q Opk missed by .04, and it dropped abour .30, but closed down a dime. This time they missed by .06, and it is playing differently, biggest single day earnings move ever.
Will see where it closes in a few hours, but fact is NOT one thing changed at Opk in the past week, nothing.
Future is still solid.
One other point many here might NOT get is OPK has invested interests in several companies, cocp, etc., with a show of hands did U KNOW that Opk RECORDS a % loss based on whatever those companies LOST??? So company A losses 1m, opk own 10% Opk records 100K loss, or some % of 100K ouch. Opk records these every Q until the cost of ownership is absorbed, SO PAPER losses mount up, cash burn not so much.
on hundreds of companies each Q. I think most longs here could likely predict opk's loss better than the analysts. When opk beats their revenue number that says they are clueless at " GUESSING " R&D, and clueless on margins, and not to mention 4k ramp up or the paper derivative swings. Keep in mind 4k is a prebiopsy test, there are only roughly 1m a year done in the US. At this point 1-2 million in sales is understandable, but could be in TIME 295m US, 695 global. This all said, regardless of the Q, opk NOW HAS near 400 MILLION in cash thanks to a Frost deal. So long is the play, the plan, 2016 = 28-32, will happen.
OPK BEATS on revenue, get it, probably not.
4k is supposedly a prebiopsy test not necessarily a replacement for psa or other tests. According to Opko there are roughly 1 million biopsies done in the US each year. Psa costs about 50 dollars, 4k was 295, and apparently now 395 and will not get coverage until July. No way to really figure uptake of 4k at this point but if we figure.
11k urologists 1 million biopsies = 90 annual on average per Dr.
In a Q that works out 22.7 biopsies per Dr. X 550 ( current Dr. ) = 4.9m revenue.
That is the best case revenue per q at this point, figuring all Dr. are performing about average number of biopsies and EVERY single person paid out of pocket. We know that is not the case, we also know unless 4k is in the guidelines uptake will crawl, but could still get traction after July. In a year, theoretically, if prior to every biopsy the Drs. are told they need do 4k before insurance will cover the biopsy, and opk is still charging 395, MAX current revenue could be roughly 1m X 395.
At this point in time if 4k is only generating 2-3M, that is about all one could expect.
solid. Could trade a few cents higher or lower, makes no difference to me.